Mon, Oct 20, 2014, 10:19 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

P L C SYSTEMS INC Message Board

  • black.dave52 black.dave52 Mar 3, 2011 12:37 PM Flag

    i see many familiar names here still posting..

    im here from way back but with new name .. sitting on a sizable unrealized loss here but its still a valuable asset for future tax planning .. instead of tossing this in the trash and taking/using the loss i decided to put it on the back burner and have added a good amount under $0.10 ..
    what are the expectations here? and please no $9.01 then gap up to $33 scomasea rants.thx

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • so spill the bean's,what was ur old handle ?

    • Two things went wring with TMR: aggressive drug regimens took away a lot of the urgent demand, and medical division of labor delivered candidates first to physicians who were more inclined to use stents if the drugs weren't enough (and boy, did they over-use stents).

      There are no such threats against RG. Best guesses at CIN prevention have failed. The potential patients are delivered first to the ones who have the choice whether to use RG. MUCH easier marketing exercise, and visibly so. It doesn't hurt that CIN is a malpractice lawyer's happy dream: nothing sways a jury like a patient able to testify about slow death in progress. The thing WILL be used if the evidence stays good.

      I'm a little concerned about the solidity of the patents. No data, but these guys have messed up in the past.

      There have been noises about making the device approval process more onerous. I think our legislators are focusing on other fights these days, and FDA seems unlikely to move quickly unless shoved. It's interesting that the rule of thumb is that to get a drug from the stage RG is at through to US marketing you'd need $100MM, while for a device $6MM looks about right.

    • familiar w/the handles here yet u have changed yours lol.

    • well if plc rg product lives upto it's expectation once fda approved $9.01 is cheap even with the added shares if lender exercize there stock options

0.00890.0000(0.00%)Sep 24 3:49 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.